| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Infectious Diseases | ||
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Infectious Diseases | ||
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Infectious Diseases |
Recent Updates
Recently added Catalysts
AN2 Therapeutics, Inc.$4.5
-0.13 (-2.81%)
D 25Pipeline Score Richly Valued Pharma · Clinical
Market Cap
146.59 M
EPS
-1.10
P/E Ratio
-3.69 $
Value Trade
890.05 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
6.74 M
Operating CF
-12.07 M
Total Assets
87.49 M
Total Liabilities
5.73 M
Equity
81.76 M
D/E Ratio
12,345
3.19 %
Week
26.63 %
1 Month
355.91 %
3 Month
357.55 %
6 Month
-71.22 %
5 Year
-71.22 %
All Time
Cash Data
Cash Position
85.29 M
Monthly Burn
4.02 M
Runway
19.2 mo
Burn Trend
SEC Filing
May 11, 2026
Overview
Volume
591.72 K
52 Week Range
1 - 6.91
% held by Insiders
26.74 %
% held by Institutions
60.13 %
Enterprise Value
61.30 M
Total Shares
35.93 M
Short %
7.42 %
Float Shares
25.94 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for AN2 Therapeutics, Inc.
141Total events
6Upcoming
34Tier-1 (high impact)
2022 – 2027Coverage
Upcoming catalysts 6
2027
T1Topline Readout
Topline results for Phase 2 study of epetraborole in M. abscessus lung disease
Event history 135
Q3 2026
◆Trial InitiationEpetraboroleTrial
Plan to initiate Phase 2 trial of oral epetraborole in PV
polycythemia verasource ↗
Jun 4, 2026
▲Preclinical PoCAN2-502998Preclinical
Positive enabling data from 28-day NHP study: 100% parasite elimination
chronic Chagas diseasesource ↗
Jun 4, 2026
▲First Patient DosedAN2-502998Trial
Phase 1 FIH study completed with favorable safety and tolerability
chronic Chagas diseasesource ↗
Jun 2026
Jun 2026
◆Trial InitiationTrial
Second oncology compound to enter development
Oncology (ENPP1 and PI3K targets)source ↗
May 19, 2026
◆Oral PresentationPresentation
Participation in 2026 Stifel Virtual Targeted Oncology Forum fireside chat
May 11, 2026
▲Trial InitiationEpetraboroleTrial
Phase 2 investigator-initiated trial commenced for M. abscessus lung disease
M. abscessus lung diseasesource ↗
May 11, 2026
▲Trial CompletionAN2-502998Trial
Phase 1 first-in-human clinical trial dosing completed
chronic Chagas diseasesource ↗
May 11, 2026
▲Development Candidate NominationPreclinical
ENPP1 candidate declared for solid tumors, advancing from early research into development
solid tumorssource ↗
Q2 2026
◆Topline ReadoutAN2-502998Clinical Data
Data expected from Phase 1 first-in-human trial and non-human primate efficacy study
chronic Chagas diseasesource ↗
Mar 31, 2026
▲Trial InitiationEpetraboroleTrial
Initiation of Phase 2 investigator-initiated clinical trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease
Mycobacterium abscessus Complex Lung Diseasesource ↗
Drug Pipeline Intelligence
D25
Pipeline Score $10M
Pipeline ValueRichly Valued
Valuation Signal2
Drugs Scored0.1x
rNPV / MCap Top 25%
Micro Cap (rank 685 of 912)
Percentile RankAN2 Therapeutics, Inc. faces pipeline headwinds (25/100), with $140M risk-adjusted pipeline value, led by Epetraborole in Healthy Volunteers (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Epetraborole Small molecule | Mycobacterium Abscessus Infection | Phase 2 | NCT07301320 | 14% | $70M | RECRUITING | 84 | - | - | May 1, 2028 | ELEVATED_RISK | MEDIUM May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
AN2-502998 | Chronic Chagas disease | Phase 1 | 2026-06-04 | Parasite elimination was achieved in 100% of nonhuman primates naturally infected with Trypanosoma cruzi after a 28-day treatment with AN2-502998, supporting its advancement to Phase 2 studies for chronic Chagas disease. Read More | AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease Parasite elimination achieved with 28-day treatment in 100% of nonhuman primates (NHPs Read More | |
AN2-502998 | Chronic Chagas disease | Phase 1 | 2026-06-04 | Parasite elimination was achieved in 100% of nonhuman primates naturally infected with Trypanosoma cruzi after a 28-day treatment with AN2-502998, supporting its advancement to Phase 2 studies for chronic Chagas disease. Read More | AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease Parasite elimination achieved with 28-day treatment in 100% of nonhuman primates (NHPs Read More | |
AN2-502998 | Chronic Chagas disease | Phase 1 | 2026-06-04 | Parasite elimination was achieved in 100% of nonhuman primates naturally infected with Trypanosoma cruzi after a 28-day treatment with AN2-502998, supporting its advancement to Phase 2 studies for chronic Chagas disease. Read More | AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease Parasite elimination achieved with 28-day treatment in 100% of nonhuman primates (NHPs Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ANTX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ANTX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ANTXAN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease Parasite elimination achieved with 28-day treatment in 100% of nonhuman primates (NHPs
AN2 Therapeutics announced positive results from studies on their oral therapeutic, AN2-502998, which targets chronic Chagas disease. The treatment achieved complete parasite elimination in 100% of nonhuman primates over a 28-day period, with a favorable safety profile demonstrated in Phase 1 human trials. The company is moving forward with plans to initiate a Phase 2 study, aiming to address the unmet medical need for an effective, well-tolerated treatment for this disease that affects millions globally. The promising data supports their goal of developing the first FDA-approved therapy for chronic Chagas disease in adults.
Read more →ANTX▲ +6.5%on this news
AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference
AN2 Therapeutics is scheduled to present at the 2026 Jefferies Global Healthcare Conference. Details regarding the presentation content or specific topics have not been disclosed. The event is expected to provide insights into the company's developments and future plans.
Read more →ANTX▲ +5.8%on this news
AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights
AN2 Therapeutics has released its financial results for the first quarter of 2026, along with updates on its business and scientific developments. The report highlights the company's ongoing efforts and strategies in the biopharmaceutical sector. Specific details regarding financial performance and scientific advancements were not disclosed in the provided text.
Read more →ANTXAN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum
AN2 Therapeutics is set to participate in the 2026 Stifel Virtual Targeted Oncology Forum. This event will provide a platform for the company to discuss its developments in oncology. Further details regarding the agenda or specific topics to be covered were not provided in the announcement.
Read more →ANTXAN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease
AN2 Therapeutics has announced the initiation of a Phase 2 investigator-initiated clinical trial for Epetraborole targeting Mycobacterium abscessus complex lung disease. This trial aims to evaluate the efficacy and safety of the treatment in affected patients. Further details regarding the trial design and expected outcomes were not disclosed.
Read more →ANTX▲ +6.6%on this news
AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights
AN2 Therapeutics reported its financial results for Q4 and full year 2025, highlighting the advancement of oral epetraborole into a Phase 2 study for polycythemia vera. The company is also preparing to initiate two additional Phase 2 studies in chronic Chagas disease and M. abscessus complex lung disease. Despite a reduced net loss compared to the previous year, the company continues to face financial challenges.
Read more →ANTX▲ +84.2%on this news
AN2 Therapeutics Announces $40 Million Private Placement Financing
AN2 Therapeutics has announced a private placement financing expected to yield approximately $40 million. The deal involves selling over 8 million shares at $2.85 each, with participation from several institutional investors. The closing is anticipated on March 10, 2026, pending customary conditions. The company plans to register the shares for resale.
Read more →ANTX▲ +26.4%on this news· ran to +395% by day 3shared move
AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV)
AN2 Therapeutics plans to advance oral epetraborole into a Phase 2 study for polycythemia vera (PV), a blood cancer. The study is expected to start in Q3 2026, with potential data readouts beginning in Q4 2026. Epetraborole has shown promising results in reducing hematocrit levels and is well tolerated in trials. The company aims to address the unmet needs in PV treatment.
Read more →ANTXAN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare Conference
AN2 Therapeutics, Inc. announced that its CEO, Eric Easom, will participate in a fireside chat at the Leerink Global Healthcare Conference on March 10, 2026. The event will be accessible via webcast, with an archived replay available for 30 days. AN2 focuses on developing novel therapeutics from its boron chemistry platform for various diseases.
Read more →ANTXAN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights Advancing Phase 1 program in Chagas Disease; Phase 2 planning underway Clinical-stage M. abscessus program advan
AN2 Therapeutics reported its Q3 2025 financial results, highlighting advancements in its clinical programs. The company is progressing with its Phase 1 trial for AN2-502998 aimed at treating Chagas disease and plans to initiate a Phase 2 study. Additionally, a collaboration with GSK to target tuberculosis has been established, backed by renewed funding from the Gates Foundation. Financially, the company reported a net loss of $9 million for the quarter, reflecting reduced R&D costs due to decreased clinical trial expenses.
Read more →ANTXInvestor Overview June 2025 A N 2 T H E R A P E U T I C S . C O M Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 199
AN2 Therapeutics outlined its forward-looking strategy focusing on its boron chemistry platform at a recent investor overview. The presentation highlighted anticipated milestones in developing various therapies, including for Chagas disease and melioidosis. The company holds a strong financial position, with sufficient cash runway to support its programs into 2028. However, significant risks remain, including the uncertainty of regulatory approvals and timely patient enrollment in clinical trials.
Read more →ANTXAN2 Therapeutics Reports Data from the Phase 3 Portion of Previously Terminated EBO-301 Study and Outlines Future Milestones from Boron Chemistry Pipeline EBO-301 truncated Phase 3 study (n=97) misses primary endpoint; r
AN2 Therapeutics reported the results from the Phase 3 EBO-301 study, which failed to meet its primary endpoint related to Quality of Life in patients with advanced MAC lung disease. Despite these disappointing outcomes, the company sees potential for its lead candidate, epetraborole, in other non-tuberculous mycobacterial diseases. AN2 is focusing on its boron chemistry pipeline, with plans for new clinical trials in Chagas disease and melioidosis. The company has extended its financial runway into 2028 and aims to optimize operational efficiency while pursuing new drug developments.
Read more →ANTXAN2 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business and Scientific Highlights Phase 3 topline data expected 2Q25 for epetraborole in patients with treatment-refractory MAC lun
AN2 Therapeutics reported its fourth quarter and full year 2024 financial results, highlighting significant milestones in its drug development pipeline. The company anticipates topline data for its Phase 3 trial of epetraborole in patients with treatment-refractory MAC lung disease in Q2 2025, building on positive Phase 2 findings. A Phase 1 study for AN2-502998 targeting Chagas disease is expected to begin in mid-2025, along with a Phase 2 proof of concept trial for melioidosis planned for later in the year. The financial outlook remains stable, with expected cash reserves funding operations into 2027 despite a recorded net loss for the year.
Read more →ANTXAN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline Epetraborole-treated patients demonstrated clinical improvements in
AN2 Therapeutics reported its financial results for the third quarter of 2024, highlighting significant clinical improvements in patients treated with its drug candidate epetraborole for treatment-refractory Mycobacterium avium Complex. The company plans to engage with the FDA to discuss the potential reinitiation of a pivotal Phase 3 clinical study. Additionally, AN2 has achieved a 50% reduction in expenditures and has sufficient cash resources to fund operations through 2027. The ongoing development of its boron chemistry pipeline was also emphasized, with plans for preclinical studies targeting chronic Chagas disease and melioidosis.
Read more →ANTXAN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan
AN2 Therapeutics has implemented a limited duration stockholder rights plan set to expire on August 15, 2025, due to a significant accumulation of stock by BML Investment Partners, who hold 19.3% of the company's shares. This plan aims to ensure fair treatment of all stockholders and protect against any coercive control tactics. Under the plan, shareholders will receive rights enabling them to purchase preferred stock at a specific price, which can be triggered under certain acquisition scenarios. The announcement highlights the company’s focus on maintaining its governance and protecting its stockholder base amidst potential takeover threats.
Read more →ANTX▲ +5.8%on this newsshared move
AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights Cash, cash equivalents, and investments of $104.5 million at
AN2 Therapeutics, Inc. reported its second-quarter financial results, highlighting a cash position of $104.5 million that will fund operations through 2027. The company announced the termination of the EBO-301 trial for epetraborole in MAC lung disease, as the trial did not meet key efficacy endpoints. However, it maintains a promising pipeline with upcoming clinical trials for candidates targeting Chagas disease and melioidosis, alongside a research focus on infectious diseases and oncology. Despite setbacks, the company is well-positioned financially and scientifically to navigate future developments.
Read more →ANTX▲ +6.9%on this news· ran to -58% by day 1shared move
AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease EBO-301 study to be discontinued following topline results from
AN2 Therapeutics has announced the discontinuation of its EBO-301 Phase 2/3 study evaluating epetraborole for treatment-refractory MAC lung disease. Despite achieving the primary objective regarding patient-reported outcomes, key secondary endpoints did not show significant efficacy. The company plans to focus on its internal boron chemistry platform and restructuring efforts expected to extend its cash runway through 2027. This disappointing outcome underscores the challenges of developing new therapies for MAC lung disease.
Read more →ANTXAN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights Plan to report Phase 2 topline results in August 2024 from ongoing Phase 2/3 trial (EBO-301) in treatment-refrac
AN2 Therapeutics has reported its first-quarter financial results for 2024 and provided updates on its clinical trials. The company plans to announce topline results from its Phase 2 trial (EBO-301) for treatment-refractory Mycobacterium avium Complex in August 2024. Currently, the Phase 3 enrollment is paused while unblinded Phase 2 data is reviewed, following concerns regarding efficacy. The company maintains a substantial cash position which supports its ongoing research and development efforts.
Read more →ANTXAN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights Phase 2/3 trial (EBO-301) in treatment-refractory Mycobacterium avium Complex (TR-MAC) continues
AN2 Therapeutics reported its fourth quarter and full year 2023 financial results, noting a strong cash position of $134.5 million. The company continues its Phase 2/3 trial for treatment-refractory Mycobacterium avium complex, anticipating topline results in summer 2024. Although the Phase 3 trial has paused enrollment due to potential efficacy concerns, the company remains optimistic about the treatment potential of its boron-based therapies, including epetraborole. Additionally, AN2 has signed licensing agreements to develop new therapies and has received a grant from the Bill & Melinda Gates Foundation for infectious disease research.
Read more →ANTX▼ -74.5%on this news
AN2 Therapeutics Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
Block & Leviton is investigating AN2 Therapeutics for potential securities law violations following a significant drop in share price. The firm's investigation was prompted by the company's announcement of a pause in Phase 3 enrollment of its clinical trial for epetraborole, which saw shares decline over 70% in premarket trading. Investors who have incurred losses are encouraged to contact Block & Leviton to learn about possible recovery of their investments. The situation raises concerns for investors regarding the company's compliance with securities regulations.
Read more →ANTXAN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights • Enrollment well underway in Phase 3 part of pivotal Phase 2/3 study of epetraborole in treatment-refrac
AN2 Therapeutics reported financial results for the third quarter of 2023, highlighting significant progress in clinical trials for epetraborole, a treatment for MAC lung disease. The company has commenced enrollment in the Phase 3 part of its pivotal trial and is set to present Phase 2 data by summer 2024. Financially, AN2 has a cash position of $150.2 million, sufficient to support operations through summer 2025, though it has reported a net loss of $16.7 million for the quarter. Furthermore, partnerships with the Gates Foundation and the University of Georgia Research Foundation underscore the company's commitment to addressing critical health issues.
Read more →ANTX▼ -5.6%on this news
AN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium complex (MAC) Lung Disease Company announces Phase 2 part of the EBO-301 trial is n
AN2 Therapeutics has launched the Phase 3 portion of its Phase 2/3 clinical trial evaluating epetraborole for treatment-refractory Mycobacterium avium complex lung disease. The Phase 2 part of the trial is fully enrolled with 80 patients, and topline results are expected by summer 2024. The trial aims to support regulatory filings in the U.S. and Japan, with an anticipated enrollment of approximately 230 patients in Phase 3. The FDA has provided several designations to epetraborole, indicating a positive outlook for its development and approval as a treatment.
Read more →ANTXAN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common Stock Menlo Park, CA
AN2 Therapeutics, a clinical-stage biopharmaceutical company, announced the pricing of its underwritten offering of common stock amounting to $70 million. The offering includes 7,777,778 shares priced at $9.00 each, which is set above the current closing price. Notable investors participating in the offering include RA Capital Management and Janus Henderson Investors. The transaction is expected to close around August 18, 2023, pending customary conditions.
Read more →ANTXAN2 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights Sufficient patients in screening expected to complete enrollment in Phase 2 portion of pivotal Phase 2/3 study of epetraborole in treat
AN2 Therapeutics reported its financial results for Q2 2023, highlighting a crucial milestone in their Phase 2/3 study of epetraborole for treatment-refractory Mycobacterium avium complex lung disease. The company expects to complete enrollment in the Phase 2 study soon and aims to begin Phase 3 in September 2023. They currently possess a cash reserve of over $95 million, which should fund operations through late 2024. However, they also reported a net loss increase to $15.8 million, largely driven by higher R&D expenses.
Read more →ANTXAN2 Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights • Nearly 80 clinical sites active in pivotal Phase 2/3 trial of epetraborole in treatment-refractory Mycobacterium avium complex
AN2 Therapeutics reported its first quarter 2023 financial results, highlighting nearly 80 clinical sites active in a pivotal Phase 2/3 trial for epetraborole, aimed at treating treatment-refractory Mycobacterium avium complex lung disease. The company is seeing promising momentum in Asia-Pacific regions, particularly in Japan, South Korea, and Australia. Despite a significant net loss of $15.3 million for the quarter, they maintain a robust cash position of $88.5 million, expected to sustain operations through mid-2024. The company aims to complete enrollment in the Phase 2 portion of the trial by mid-2023, with the Phase 3 trial to follow immediately after.
Read more →ANTXAN2 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights • Approaching 60 clinical sites participating in pivotal Phase 2/3 trial of epetraborole in treatment-refractory M
AN2 Therapeutics has reported its financial results for 2022, highlighting progress in the pivotal Phase 2/3 trial of epetraborole for treatment-refractory MAC lung disease, nearing enrollment of 60 clinical sites across several countries. The company has achieved important designations from FDA and PMDA, indicating potential for regulatory approval in major markets. Additionally, funding of up to $17.8 million from NIAID will assist further development of epetraborole for acute systemic melioidosis. Though facing challenges such as reported financial losses and increasing R&D expenses, AN2's trajectory in the global health market remains optimistic.
Read more →ANTXAN2 Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates • U.S. Enrollment Ongoing in EBO-301 Pivotal Phase 2/3 Clinical Trial of Epetraborole in Treatment-Refractory MAC Lung Di
AN2 Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates -U.S. Enrollment Ongoing in EBO-301 Pivotal Phase 2/3 Clinical Trial of Epetraborole in Treatment-Refractory MAC Lung Disease; Plan to Include Japanese Patients in Trial -Awarded Contrac
Read more →ANTX▲ +10.1%on this news· ran to +25% by day 3
AN2 Therapeutics to Present at Upcoming Investor Conferences
MENLO PARK, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that company manageme
Read more →ANTX▼ -8.4%on this news
AN2 Therapeutics to Present New Epetraborole Data at IDWeek 2022
Enrollment Ongoing in Phase 2/3 Pivotal Trial of Epetraborole in Treatment- Refractory MAC Lung Disease MENLO PARK, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for ra
Read more →ANTXAN2 Therapeutics Provides Update on Epetraborole Ex-U.S. Development Plan in Treatment-Refractory MAC Lung Disease Epetraborole Data from Recently Completed Phase 1 Study in Japanese Subjects Supports Use of Once Daily,
AN2 Therapeutics Provides Update on Epetraborole Ex-U.S. Development Plan in Treatment-Refractory MAC Lung Disease Menlo Park, CA October 6, 2022 AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chroni
Read more →ANTX▼ -10.2%on this news
AN2 Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
MENLO PARK, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that Eric Easom, Pres
Read more →ANTX▲ +6.4%on this news· ran to +96% by day 3
AN2 Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates • Enrolling U.S. Patients in the EBO-301 Pivotal Phase 2/3 Trial of Epetraborole in Treatment-Refractory MAC Lung Diseas
AN2 Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates -Enrolling U.S. Patients in the EBO-301 Pivotal Phase 2/3 Trial of Epetraborole in Treatment-Refractory MAC Lung Disease; Topline Results from Phase 2 Part of Trial Expected in Mid-2023
Read more →ANTXAN2 Therapeutics Initiates Pivotal Phase 2/3 Trial Evaluating Epetraborole for Treatment-Refractory MAC Lung Disease AN2 is developing epetraborole as a once-daily, orally administered treatment with a novel mechanism of
AN2 Therapeutics Initiates Pivotal Phase 2/3 Trial Evaluating Epetraborole for Treatment-Refractory MAC Lung Disease Menlo Park, CA June 29, 2022 AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic
Read more →ANTX▲ +6.9%on this news· ran to +17% by day 3
AN2 Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates • On Track for Several Milestones in 2022, and Supported by Strong Balance Sheet from Upsized Initial Public Offering &#x
AN2 Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates -On Track for Several Milestones in 2022, and Supported by Strong Balance Sheet from Upsized Initial Public Offering -Continued Progress Advancing Epetraborole Clinical Program with Enro
Read more →ANTX▼ -19.7%on this newsshared move
AN2 Therapeutics Appoints Maggie FitzPatrick to its Board of Directors Menlo Park, CA
AN2 Therapeutics Appoints Maggie FitzPatrick to its Board of Directors CA May 9, 2022 AN2 Therapeutics, Inc., (NASDAQ: ANTX) a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announce
Read more →ANTXAN2 Therapeutics Announces Pricing of Upsized Initial Public Offering
MENLO PARK, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced the pricing of its upsized initial
Read more →Competitive Position
How ANTX ranks across every disease it competes inCompetitive Position is a premium feature
See how ANTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial